natgillin/translations-raw huggingface dataset:
The humanized anti-CD40 antibody for use as in any one of claims 4-7, wherein said antibody is administered by a parenteral route, intravenous route or subcutaneous route of administration. 
Protutijelo namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 2-5, naznačeno time što se navedeno protutijelo primjenjuje parenteralnim načinom, intravenskim načinom ili supkutanim načinom primjene.
is selected from the group consisting of hydrogen and halo; 
R je odabran iz skupine koja sadrži vodik i halo;
A molecule according to claims 1 or 2, wherein the polyethylene glycol molecule is attached via a maleimide linkage. 
Molekula u skladu s patentnim zahtjevom 1, naznačena time što je molekula polietilen-glikola vezana preko maleimidne spojnice.
The wear member according to claim 1, characterized in that an opening (101) for receiving a lock (16) to secure the wear member (14) to the base (12) is included. 
Zub bagera prema zahtjevu 1, naznačen time, da je predviđen otvor (101) za prihvat zasuna (16) u svrhu osiguravanja zuba bagera (14) na bazi (12).
A method of inhibiting immune cell activation comprising administering to the cell a compound of formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein: 
PATENTNI ZAHTJEVI L In vitro postupak inhibicije aktivacije imunoloških stanica naznačen time da se sastoji od primjene na stanicu spoja formule (I):
(S)-pirlindole enantiomer or a pharmaceutically acceptable salt thereof, for use according to claims 3 and 4 for potentiating the effects of the at least one additional analgesic agent in the treatment of neuropathic pain. 
(S)-pirlindol enantiomer ili njegova farmaceutski prihvatljiva sol, najmenjen upotrebi prema patentnim zahtjevima 3 14 za potenciranje učinaka najmanje jednog dodatnog analgetskog sredstva za liječenje neuropatske boli.
A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising a composition comprising at least: at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000; and 
Oblik doziranja s produljenim otpuštanjem prema zahtjevu 12, naznačen time da sastojak sadrži barem oko 80 % (po težini) polietilen oksida koji sadrži, bazirano na reološkim mjerenjima, približnu molekulsku težinu od barem 1,000,000.
The working volume corresponds to the volume in liters of the culture in the system. 
Radna zapremina odgovara zapremini u litrama kulture u sustavu.
The nutrition according to embodiment 1 or 2 further comprising an extensively and/or partially hydrolysed protein source. 
Hrana prema zahtjevu 1 ili 2, naznačena time što nadalje sadrži iscrpno i/ili djelomično hidrolizirani izvor proteina.
The invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli, u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje depresivnih poremećaja.
29.9 g of the compound of the invention as mesylate salt was obtained. 
Dobiveno je 29.9 g spoja iz ovoga izuma u obliku mesilatne soli.
The compound of any of claims 5-8, further comprising an additional peptide component that extends the in vivo retention of the compound; optionally wherein the additional peptide component is an albumin binding peptide. 
Spoj prema zahtjevu 9, 10 ili 11, dalje sadrži dodatnu peptidnu komponentu koja produžuje in vivo retenciju spoja; po izboru je dodatna peptidna komponenta peptid koji veže albumin; po izboru sadrži SEQ ID NO:39.
the C-terminal second fragment is a Clostridium difficile toxin B repeating domain fragment and comprises at least 100 amino acids, wherein Clostridium difficile toxin B is represented by SEQ ID NO:2; 
drugi fragment je fragment ponavljane domene toksina B i sadrži najmanje 100 aminokiselina; proksimalni kraj prvog fragmenta se nalazi unutar prvog ponavljanog dijela;
Mix 30.0 g of prepared sand accurately weighed with 1.5-2.0 g material accurately weighed and dry to constant weight at 60°C under reduced pressure 50 mm Hg (6.7 kPa). 
Pomiješa se 30,0 g pripremljenog pijeska točno izvaganog, sa 1,5-2,0 g materijala točno izvaganog, i suši do konstanine mase pri 60 "C pod sniženim tlakom pri 50 mmHg (6,7 kPa).
Thus, in one embodiment, the invention relates to crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl) piperidin-4-yl ester characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2θ values selected from 6.6±0.1, 13.1±0.1, 18.6±0.1, 19.7±0.1, and 20.2±0.1. 
1-(2-([4-(4-karbamoilpiperidin-1ilmetil)benzoillmetilamino)etiDpiperidin-4-il estera, naznačena time, da vrijednosti 20 njezina difraktograma rentgenske analize praha obuhvaćaju difrakcijske maksimume 6.6+0.1, 13.1+0.1, 18.6=:0.1, 19.74#0.1 120.2 #0.1 1 ima pet ili više dodatnih 20 vrijednosti difrakcijskih maksimumima odabranih između 8.8+0.1, 10.1#0.1, 11.440.1,
A method as claimed in any preceding claim further comprising analyzing envelope characteristics of separated bands to identify a breath candidate, or comparing the values between identified minimum and said proportion of a maximum or proportional rise from a minimum, and optionally comprising identifying the degree of mathematic monotonicity of at least one separated band within a predetermined time, and/or optionally comprising identifying a breath candidate if a breath signal has a comparable envelope shape in two or more frequency bands, and/or optionally comprising using the monotonicity information to identify the intervals of time during which the search of minimums or maximums should take place. 
Postupak kao što je navedeno u bilo kojem od prethodnih zahtjeva, dalje sadržeći analizu karakteristika ovojnice odvojenih pojaseva zbog identifikacije kandidata daha, ili usporedbu vrijednosti između identificiranog minimuma 1 navedenog dijela maksimuma ili proporcionalnog rasta od minimuma, i opcionalno sadržeći identifikaciju stupnja matematičke monotonosti barem jednog odvojenog pojasa unutar predodređenog vremena, i/ili opcionalno sadržeći identifikaciju kandidata daha ako signal daha ima usporediv oblik ovojnice u dva ili više frekvencijska pojasa, i/ili opcionalno sadržeći korištenje podataka o monotonosti zbog identifikacije vremenskih intervala tijekom kojih bi se trebala odvijati potraga za minimumima ili maksimumima.
This parameter refers to the depth to which a spiral drops in a period of 12 seconds, when released on the surface of the whipped cream and is measured with a Slagsahne Prufgerat apparatus according to the previously mentioned method described by Moor & Rapaille (1982). 
Taj se pokazatelj odnosi na dubinu do koje se utisne spirala u razdoblju od 12 sekundi nakon što se položi na površinu tučenog slatkog vrhnja, a mjeri se uređajem Slagsahne Prufgerat, ranije navedenom metodom koju su opisali Moor & Rapaille (1982).
In a particularly preferred embodiment the present process yields a light stabilising composition in accordance with the present invention in a yield of at least 20%. 
U naročito poželjnom ostvarenju, sadašnji postupak daje pripravak za stabiliziranje na svjetlo u skladu sa sadašnjim izumom s prinosom od najmanje 20%.
The combined ethyl acetate extracts were dried (MgS04) and evaporated to give ethyl 4-(2-azidoethoxy)-acetoacetate as a brown oil, which was shown by g.l.c. to be 73% pure. 
Spojeni etilacetatni ekstrakti se suše (MgSO,) 1 ispare tako da 4-(2-azidoetoksijacetoacetat kao smeđe ulje, za koje je pokazano pomoću g.l.c, da je 73% čisto.
After 1-hour incubation at 37° C. with shaking the washing procedure was repeated and bound antibodies were detected with HRP conjugated with goat anti-rabbit diluted 1:10,000 in assay buffer. 
Nakon jednosatne inkubacije pri 37 "C uz potresanje, postupak ispiranja se ponovi i vezana protutijela detektiraju sa HRP-om konjugiranim sa kozjim protu-zečjim razrijeđenim u omjeru 1:10000 u puferu za test.
wherein PG is a nitrogen protecting group; 
(KK gdje je PG skupina koja štiti dušik;
The process according to claim 1, in which said solid residue is separated from the effluent of the enzymatic partial hydrolysis. 
Postupak prema jednom od zahtjeva 1 do 3, naznačen time što se navedeni kruti ostatak odvaja od efluenta iz koraka enzimske hidrolize.
Concentrator according to claim 19, further adapted to perform the operation of determining the amount (L) of said periodically measured and stored consumption related data also on the basis of parameters, especially a time interval, previously stored in said concentrator (C) from a centralized management facility (AMM). 
Sabirnik prema patentnom zahtjevu 19, nadalje prilagođen za provođenje operacija utvrđivanja količine (L) navedenih periodički izmjerenih i pohranjenih podataka vezanih uz potrošnju i na temelju parametara, posebno vremenskih intervala prethodno pohranjenih u navedenom sabirniku (C) iz središnje upravljačke jedinice (AMM).
The use of a composition of any one of claims 2-4, for the manufacture of a medicament for treating BCR-ABL positive leukemia. 
Uporaba sastava prema jednom od zahtjeva 2 do 4, naznačena time, da je za proizvodnju lijeka za liječenje leukemije pozitivne na BCR-ABL.
each R1 linked to the carbon atoms at positions 3 and 5 of the piperidine ring is independently —CH2—ONO2; and R1 linked to the carbon atom at position 4 of the piperidine ring is H; 
svaki od R1 vezan na ugljikove atome u položajima 3 i 5 piperidinskog prstena je skupina donor dušikovog monoksida -CH2-ONO2; i R1 vezan na ugljikov atom u položaju 4 piperidinskog prstena je H (ovdje identificirani kao spojevi redom 6a1, 6a2 i 6a3);
The method according to claim 11, wherein the applied polymer material is formed by a stamp or the like. 
Zatvarač prema zahtjevu 9 ili zahtjevu 10, naznačen time da se primijenjeni polimerni materijal oblikuje pomoću uboda ili slično.
Unlimiting examples of surfactants include water-soluble or water dispersible nonionic, semi-polar nonionic, anionic, cationic, amphoteric, or zwitterionic surface-active agents; or any combination thereof. Other solubilizing agents include but not necessarily limited to vitamin E substance and its derivatives; monohydric alcohol esters such as trialkyl citrates, lactones and lower alcohol fatty acid esters; nitrogen-containing solvents; phospholipids; glycerol acetates such as acetin, diacetin and triacetin; glycerol fatty acid esters such as mono-, di- and triglycerides and acetylated mono- and diglycerides; propylene glycol esters; ethylene glycol esters; and combinations thereof. 
Oralni farmaceutski pripravak s kontroliranim oslobađanjem prema zahtjevu 1, naznačen time da nadalje sadrži sredstvo (sredstva) za otapanje koja se odabiru između surfaktanata kao što su neionske, semipolarne, anionske, kationske, amfoterne ili zwitterionske površinski aktivne tvari topive u vodi; ciklodekstrin i njegovi derivati; lipofilne tvari; vitamin E i njegovi derivati; esteri nižih alkohola i masnih kiselina; otapala koja sadrže dušik; fosfolipidi; glicerol acetati kao što su acetin, diacetin i triacetin, esteri glicerola i masne kiselina kao što su mono-, di- i trigliceridi te acetilirani mono- i digliceridi; esteri propilen glikola; esteri etilen glikola ili bilo koja kombinacija istih.
A compound, salt or composition according to claim 6 wherein the neoplastic disease is selected from lung cancer, head and neck cancer, central nervous system cancer, prostate cancer, testicular cancer, colorectal cancer, pancreatic cancer, liver cancer, stomach cancer, biliary tract cancer, esophageal cancer, gastrointestinal stromal tumor, breast cancer, cervical cancer, ovarian cancer, uterine cancer, leukemia, lymphomas, multiple myeloma, melanoma, basal cell carcinoma, squamous cell carcinoma, bladder cancer, renal cancer, sarcoma, mesothelioma, thymoma, myelodysplastic syndrome and myeloproliferative disease. 
Spoj, sol ili kompozicija, prema Zahtjevu 6, naznačeni time, što se spomenuta neoplastična bolest bira između slijedećih: kancer pluća, kancer glave i vrata, kancer središnjeg živčanog sustava, kancer prostate, kancer testisa, kolorektalni kancer, kancer pankreasa, kancer jetre, kancer želuca, kancer žučnog trakta, kancer jednjaka, gastrointestijalni stromalni tumor, kancer dojke, kancer cerviksa, kancer jajnika, kancer uterusa, leukemija, limfomi, multipli mijelom, melanom, karcinom bazalnih stanica, karcinom skvamoznih stanica, kancer mjehura, kancer bubrega, sarkom, mezotelioma, timom, mijelodisplastični sindrom i mijeloproliferativna bolest.
The compound for use as claimed in claim 3, wherein said visual cycle product is lipofuscin or N-retinylidene-N-retinylethanolamine (A2E). 
Pripravak za uporabu kako je zatraženo u zahtjevu 8, naznačen time da navedeni vizualni ciklički produkt je lipofuscin ili N-retiniliden-N-retiniletanolamin (A2E).
watering said beam-like block of wood (12) obtained in step (i), 
(ii) potapanje u vodu navedenog bloka od drva koji ima oblik grede (12) i koji je dobiven u fazi (i)
FEC decoding the bit-deinterleaved Physical Layer Pipe data. 
FEC dekodiranje podataka cijevi fizičke razine raspletenih bitova.
A compound of Formula I or Formula II: or a pharmaceutically acceptable salt or ester, thereof; 
Spoj sa formulom I ili sa formulom II: [image] ili farmaceustki prihvatljiva sol ili ester tog spoja, gdje:
or a pharmaceutically acceptable salt thereof. The compound of claim 1 or any one of claims 9 to 11, wherein the compound of Formula I is the compound of the table below, 
Farmaceutski sastav prema zahtjevu 1 ili zahtjevu 10, gdje je spoj formule I spoj iz donje tablice, ili njegova farmaceutski prihvatljiva sol.
The composition or vaccine of paragraph 1, wherein the HVT vector comprises a heterologous polynucleotide coding for and expressing a Newcastle Disease Virus F (NDV-F) antigen having at least 80% sequence identity to the amino acid sequence as set forth in SEQ ID NO:2,4, 6,33, 35, or 37. 
Sastav ili cjepivo za uporabu prema zahtjevima 1-2, naznačen/o time, da sekvenca proteina NDV-F ima najmanje 90% identiteta sekvence prema sekvenci koja je prikazana u SEQ ID NO: 2, 9, 50, 52 ili 54.
The method of claim 1 wherein the crosslinked amine polymer comprises the residue of an amine corresponding to Formula 2b: wherein 
Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-5, gdje umreženi aminski polimer sadrži ostatak amina koji odgovara Formuli 2b:
contacting off-gas from the pyrolysis and/or gasification steps with a 3-way catalyst external to the chamber to convert carbon monoxide and hydrocarbons in the off-gas into carbon dioxide and water; 
- < dovođenje plina oslobođenog tijekom faze pirolize i/ili uplinjavanja u kontakt s nekim oksidacijskim katalizatorom da bi se ugljični monoksid i hidrokarboni iz oslobođenog plina konvertirali u ugljični dioksid i vodu;
has an inadequate response to oral antibiotics, is intolerant to oral antibiotics, or has a contraindication to oral antibiotics; or 
(i) ima neadekvatan odgovor na oralne antibiotike, ne tolerira oralne antibiotike, ili ima kontraindikaciju na oralne antibiotike; ili
Following heating, the pipework is chased with additional water, buffering agents and optional flavourings are added to the cooked mass and the pH of the mass is adjusted, for example, with sodium hydroxide. 
Poslije zagrijavanja, kroz cijevi se propušta dodatna količina vode, u kuhanu masu se dodaju puferirajuća sredstva 1 izborno aromati i pH mase se podešava, na primjer, sa natrijevim hidroksidom.
the asparagine at position 11 of the BC loop (SEQ ID NO: 34) is substituted with an amino acid selected from the group consisting of C, H, Q, S, and Y; 
asparagin na položaju 11 u petlji BC (SEQ ID NO: 34) je zamijenjen aminokiselinom koju se bira iz skupine koju čine A, C, F, H, P, Q, R, S i Y.
The anhydrous crystalline monophosphoric acid salt of claim 2 having form A wherein the form A has an X-ray powder diffraction pattern comprising a characteristic peak, in terms of 2θ, at about 15°. 
Bezvodna kristalinična sol monofosforne kiseline prema zahtjevu 2 koja ima oblik A gdje oblik A ima uzorak rendgenske difrakcije praška (engl.
The solid was then filtered and the filtrate was concentrated in vacuo. 
Čvrsta supstanca je zatim filtrirana i filtrat je koncentriran in vacuo.
Paragraph 144. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and one or more compounds selected from the group consisting of: 
Farmaceutski pripravak, naznačen time da sadrži farmaceutski prihvatljiv nosač i jedan ili više spojeva odabranih iz skupine koja sadrži: 3-Fluoro-N-(2'-trifluorometil-bifenil-4-il)-izonikotinamid; 3-Fluoro-N-(2'-metil-bifenil-4-il)-izonikotinamid; 3-Fluoro-N-(3'-trifluorometil-bifenil-4-il)-izonikotinamid;
The preferred film forming agents of the present invention show a surprising potentiating effect when employed with Equisetum herb extracts. 
Poželjni agens koji tvori film iz ovog izuma pokazuje iznenađujući potencijalni učinak kad se koristi s biljnim ekstraktima Equisetuma.
wherein each instance of the radio network equipment comprises radio circuitry and processing circuitry operatively connected to the radio circuitry, wherein the processing circuitry of the radio network equipment is configured to: 
Sustav koji sadrži jednu ili više instanci opreme za radio mrežu, gdje svaka instanca opreme za radio mrežu uključuje radio sklopovlje i sklopovlje za obradu radno spojeno s radio sklopovljem, gdje oprema za radio mrežu može tako raditi da komunicira s bežičnim uređajem u mreži za bežične komunikacije, gdje je sklopovlje za obradu u opremi za radio mrežu konfigurirano za:
for use in the treatment of an eye disease associated with inflammation and / or vascular proliferation in a subject; wherein the eye disease is selected from the group comprising diabetic retinopathy, corneal edema, anterior and posterior uveitis, pterygium, corneal diseases, dry eye, conjunctivitis, allergy- and laser-induced exudation, non-age related macular degeneration, macular edema, age-related macular degeneration and ocular von Hippel-Lindau disease. 
za uporabu u liječenju bolesti oka povezane s upalom i/ili vaskularnom proliferacijom u subjektu; naznačen time što je bolest oka odabrana iz skupine koja sadrži dijabetsku retinopatiju, edem rožnice, prednji i stražnji uveitis, pterigij, bolesti rožnice, suho oko, konjunktivitis, izlučivanje uzrokovano alergijom i laserom, makularnu degeneraciju nepovezanu s dobi, makularni edem, makularnu degeneraciju povezanu s dobi i očnu von Hippel-Lindau bolest.
A process according to any of claims 1-3 wherein at least 20% (w/w) of the lignocellulosic biomass has a fibre size above 26 mm. 
Postupak prema bilo kojem od patentnih zahtjeva 1-3, naznačen time što najmanje 20% (tež./tež.) lignocelulozne biomase ima veličinu vlakana preko 26 mm.
Embodiment 8. A pharmaceutical composition made by mixing a compound of embodiment 1 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav koji se dobiva miješanjem spoja prema bilo kojim zahtjevima 1 do 13 i farmaceutski prihvatljivog nosača.
In this example, the duration of the active OFDM symbol may be 448 µs (at 4k FFT mode for 8MHz bandwidth CATV systems) or 597 µs (at 4k FFT mode for 6MHz bandwidth CATV systems). 
Postupak prema zahtjevu 1, gdje je vrijednost aktivnog OFDM polja trajanja simbola jedna od 448 us na 4k brzih Fourierovih transformacija (FFT), mod za prijenosni sustav od 8 MHz širine pojasa 1 448 x (8/6) us na 4k FFT mod za prijenosni sustav od 6 MHz širine pojasa.
The composition obtained according to the process of the invention, in particular the composition of EPA and DHA ethyl esters, is therefore conform to the commercial products obtained by molecular distillation and to the products already known for pharmaceutical, para-pharmaceutical, dietetic, alimentary use, etc. 
Pripravak dobiven prema postupku iz izuma, naročito pripravak etil estera EPA i DHA, je prema tome sukladan komercijalnim produktima dobivenim molekularnom destilacijom i produktima već poznatima za farmaceutsku, parafarmaceutsku, dijetetsku, prehrambenu upotrebu, itd.
is selected from hydrogen, unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, halogen, 
se bira između vodika, nesupstituiranog alkila, supstituiranog ili nesupstituiranog cikloalkila, supstituiranog ili nesupstituiranog alkenila, supstituiranog ili nesupstituiranog arila, supstituiranog ili nesupstituiranog heterocikla, halogena;
The method of any of Paragraphs 82-90, wherein the effective amount of the compound is a twice daily dose of from 25 milligrams to 200 milligrams. 
Spoj za uporabu prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time što učinkovita količina je dnevna doza od 25 miligrama do 150 miligrama.
a third outer layer 13, which is substantially hydrophilic and is suitable for permeation of vapor-phase perspiration, absorption of liquid-phase perspiration that arrives from the first layer 11, and distribution of said liquid-phase perspiration over its surface so that it can evaporate outwardly. Said first layer 11, said second layer 12 and said third layer 13 are joined so as to form a single body. 
- - trećeg vanjskog sloja (13, 113, 213), koji je u biti hidrofilan i pogodan je za propuštanje znoja u parovitom stanju, za apsorpciju tekuće faze znoja koji dolazi iz prvog sloja (11, 111, 211, 411) 1 za raspodjelu navedene tekuće faze znoja na velikoj površini tako da se može ispariti prema van,
The method of claim 6, wherein the amino acid sequence of the IL-22 Fc fusion protein has at least 99% sequence identity to the amino acid sequence of SEQ ID NO:8. 
Fuzijski protein Fc IL-22 prema zahtjevu 1, naznačen time, da aminokiselinska sekvenca ima najmanje 96%, najmanje 97%, najmanje 98%, ili najmanje 99% identiteta sekvence prema aminokiselinskoj sekvenci odabranoj iz skupine koju čine SEQ ID NO:8 i SEQ ID NO:10.
After these two hours, transcytosis of LDL-Dil particles through endothelial cells was assessed by determination of the presence of fluorescence in the lower well of insert of coculture. 
Nakon ta dva sata, transcitoza LDL-DiI čestica kroz endotelne stanice je ocijenjena određivanjem prisutnosti fluorescencije u donjoj jamici umetnute sukulture.
each Ra, Rb and Rc are independently selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclic group; and 
Ra se bira između vodika, COR,, COOR, supstituiranog ili nesupstituiranog C;-C,> alkila, supstituiranog ili nesupstituiranog C2-Cpx_ alkenila, supstituiranog ili nesupstituiranog C2-Ci2_ alkinila, 1 supstituiranog ili nesupstituiranog C4-C;2 alkeninila;
The delivery system of claim 13, wherein a cleaner is discharged into a throttle body of the internal combustion engine to dissolve unwanted residue deposits on an internal surface or working part within the engine. 
Sustav za dovođenje prema zahtjevu 2, naznačen time da se sredstvo za čišćenje ispušta u tijelo regulatora za gas motora s unutarnjim izgaranjem radi otapanja ostataka neželjenih naslaga na unutrašnjoj površini ili radnom dijelu unutar motora.
Non-steroidal anti-inflammatories, such as sodium cromoglycate and nedocromil sodium Ketotifen 
- nesteroidna protuupalna sredstva, kao što je natrijev kromoglikat i nedokromil-natrij,
PCT International Patent Application Publication No. 
Datum objave europske prijave patenta:
The method of claim 4, wherein the therapeutic antibody or antigen-binding fragment thereof is not conjugated with a radioactive or toxic moiety. 
Sastav iz patentnog zahtjeva 24 ili 25, pri čemu navedeno protutijelo nije konjugirano s radioaktivnom ili toksičnom česticom.